免疫联合靶向治疗在晚期肝癌转化治疗中的研究进展

Advances of the conversion therapy of immune checkpoint inhibitors combined antiangiogenic targeted drugs for advanced hepatocellular carcinoma

随着肝细胞癌(HCC)发病机制研究的深入,晚期肝癌已经进入到了多种方式、多种药物联合使用的综合治疗时代,尤其是免疫治疗、免疫联合抗血管靶向治疗以及肝动脉灌注化疗等降期转化治疗取得了显著的疗效,给晚期肝癌患者带来了希望。目前免疫联合靶向药物治疗晚期肝癌已经成为了国内外研究的热点之一,阿特利珠单抗联合贝伐珠单抗(T+A)方案更是作为一线治疗方案正式写入了多个指南之中。本文就免疫联合靶向治疗研究进展、适用人群、疗效监测方面进行讨论。

With the in-depth research on the pathogenesis of hepatocellular carcinoma(HCC),ad-vanced liver cancer has entered the era of comprehensive treatment with multiple methods and combina-tions of multiple drugs. In particular,immunotherapy,immune checkpoint inhibitors combined withantiangiogenic targeted drugs and hepatic arterial infusion chemotherapy(HAIC)and other down-stageconversion therapy have achieved remarkable efficacy,bringing hope to patients with advanced livercancer. At present,immunization combined with targeted drugs for the treatment of advanced liver cancerhas become one of the research hotspots at home and abroad,and the plan of atezolizumab plus bevaci-zumab(T+A)has been officially written into several guidelines as the first-line therapy for the advancedliver cancer. This article discusses the research progress,applicable population,and efficacy monitoringof immune combined targeted therapy.